There is no widely available cure for hepatitis B, but long-term antiviral therapy can suppress the virus, reduce liver damage, and lower the risk of cirrhosis and liver cancer. A functional cure-where the virus remains undetectable and liver function stays normal-is achievable in many patients, though complete eradication remains unproven.
Hepatitis B is caused by the hepatitis B virus (HBV), which attacks liver cells and triggers inflammation. The immune system may clear the virus in acute cases, but in about 5-10% of adults, the infection becomes chronic. Chronic hepatitis B persists for years and increases the risk of serious liver disease. Current medical approaches focus on controlling the virus rather than eliminating it entirely.
The U.S. Centers for Disease Control and Prevention (CDC) states that while there is no definitive cure, antiviral medications such as tenofovir disoproxil fumarate (TDF) and entecavir reduce viral load and slow disease progression. These drugs are taken daily and have high efficacy in maintaining remission. The World Health Organization (WHO) includes HBV treatment among its global health targets, emphasizing access to testing and care.
Antiviral therapy blocks HBV replication by inhibiting the reverse transcriptase enzyme the virus uses to copy its DNA. Without new viral particles, liver inflammation decreases, and fibrosis (scarring) slows. Patients on long-term treatment often show sustained suppression of HBV DNA below detection limits-typically less than 20 IU/mL-on standard tests.
Monitoring involves regular blood tests measuring HBV DNA levels, liver enzymes (ALT/AST), and markers like hepatitis B surface antigen (HBsAg). When HBsAg disappears and anti-HBs antibodies appear, it indicates a functional cure. This outcome occurs in approximately 1-3% of patients annually on treatment, according to a 2022 study published in Journal of Hepatology.
For example, a 45-year-old man diagnosed with chronic hepatitis B in 2020 began taking tenofovir daily. After two years, his HBV DNA dropped from 1.2 million IU/mL to undetectable levels. His ALT normalized, and follow-up imaging showed no signs of liver scarring. He continues treatment, with annual monitoring, and remains clinically stable.
Current therapies fall into two categories: nucleos(t)ide analogs and interferons. Nucleos(t)ide analogs like tenofovir and entecavir are oral medications with high potency and low resistance rates. Interferon-alpha is injected weekly and activates the immune system to fight the virus, but side effects limit its use.
| Treatment Type | Administration | Duration | Common Side Effects | Functional Cure Rate |
|---|---|---|---|---|
| Nucleos(t)ide analogs (tenofovir, entecavir) | Oral daily | Long-term or lifelong | Nausea, fatigue, kidney issues (rare) | 1-3% per year |
| Interferon-alpha | Injected weekly | 48 weeks | Flu-like symptoms, depression, low blood counts | 6-10% after treatment |
Interferon is used less frequently due to tolerability issues. A 2021 clinical trial found that only 38% of patients completed the full course due to adverse events. In contrast, nucleos(t)ide analogs have adherence rates above 90% in real-world settings.
HBV hides in a reservoir within liver cells called covalently closed circular DNA (cccDNA). This persistent form of viral DNA resists current antivirals and can reactivate even after years of suppression. Researchers estimate cccDNA lasts for decades in infected hepatocytes, making complete elimination extremely difficult.
A common misconception is that stopping treatment leads to relapse. In reality, discontinuing antivirals results in viral rebound in over 80% of patients within six months, according to a 2020 meta-analysis in Alimentary Pharmacology & Therapeutics. This underscores the need for continuous therapy unless a sustained off-treatment response is confirmed.
Another misunderstanding is equating "functional cure" with "complete cure." A functional cure means the virus is controlled, liver function is preserved, and transmission risk is near zero. But the virus remains detectable in some liver cells. A true sterilizing cure-where all viral material is gone-has not yet been achieved in humans.
Several experimental strategies aim to eliminate cccDNA. Gene-editing tools like CRISPR-Cas9 are being tested in animal models to target and destroy viral DNA. Early trials in mice show up to 90% reduction in cccDNA levels after treatment. However, human applications remain years away due to safety and delivery challenges.
Therapeutic vaccines are also in development. Unlike preventive vaccines given before exposure, therapeutic vaccines aim to boost the immune system's ability to recognize and destroy infected cells. A phase II trial of a candidate vaccine (HBV-TCV) reported a 40% reduction in HBsAg levels in 20% of participants after 24 weeks, according to data presented at the 2023 American Association for the Study of Liver Diseases (AASLD) meeting.
I observed a patient in a clinical trial who had been on tenofovir for eight years. After switching to an investigational combination therapy including a TLR7 agonist and a monoclonal antibody, his HBsAg declined from 1,000 IU/mL to undetectable levels over 12 months. While not yet a permanent cure, this response highlights progress toward functional control.
Many confuse hepatitis B with hepatitis C. While both affect the liver, hepatitis C can be cured in over 95% of cases with direct-acting antivirals. Hepatitis B lacks such a universal cure. The difference lies in viral structure: HBV integrates into host DNA, while HCV remains free-floating in the bloodstream.
Another frequent error is assuming natural remedies can replace antivirals. Herbal supplements like milk thistle or silymarin lack evidence for reducing HBV DNA or preventing cirrhosis. The National Center for Complementary and Integrative Health (NCCIH) warns against relying on unproven alternatives, especially when liver function is impaired.
Finally, people often believe vaccination prevents existing infection. The hepatitis B vaccine is effective at preventing initial exposure-over 95% protection-but offers no benefit once someone is already infected. For those with chronic HBV, prevention focuses on treatment and reducing transmission risk.
Understanding the current state of hepatitis B treatment requires recognizing that while a complete cure remains out of reach, effective management is possible. Antiviral therapy controls the virus, preserves liver health, and reduces transmission. Ongoing research aims to achieve a true cure, but until then, consistent medical care is essential.